Moomoo AIのまとめ
Aurora Cannabis delivered strong fiscal 2024 Q4 results with total net revenue increasing 5% YoY to $67.4M, driven by 20% growth in global medical cannabis revenue to $45.6M. The company achieved a record annual adjusted EBITDA of $12.8M, marking its sixth consecutive quarter of positive adjusted EBITDA. Medical cannabis segment demonstrated robust performance with 66% adjusted gross margin.The company strengthened its balance sheet, ending Q4 with approximately $180M cash position and becoming debt-free in its cannabis business. Consumer cannabis revenue declined 29% YoY to $10.2M as the company prioritized high-margin international medical sales. Plant propagation revenue from Bevo remained stable at $10.4M.Looking ahead, Aurora expects mid to high teens revenue growth in Q1 2025, driven by German market expansion and Australian operations. The company remains confident in achieving positive free cash flow by December 2024, supported by continued growth in global medical cannabis sales and disciplined cost management. Adjusted SG&A was $31.6M, slightly above the $30M target due to MedReleaf Australia integration costs.
